Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
1,748
Views
1
CrossRef citations to date
0
Altmetric
Migraine
Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States
Oralee J. Varnadoa Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
https://orcid.org/0000-0001-8054-2544View further author information
Wenyu Yea Eli Lilly and Company, Indianapolis, IN, USAView further author information
, Xiaojuan Mib TechData Services Company, King of Prussia, PA, USAView further author information
, Russel Burgea Eli Lilly and Company, Indianapolis, IN, USAView further author information
& Jerry Halla Eli Lilly and Company, Indianapolis, IN, USA
https://orcid.org/0000-0002-0184-661XView further author information
Pages 149-157
|
Received 29 Sep 2022, Accepted 03 Jan 2023, Published online: 20 Jan 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.